



SIGACHI INDUSTRIES LIMITED

CIN : L24110TG1989PLC009497

To,

Date: November 14, 2025

The Manager BSE Limited P. J. Towers, Dalal Street Mumbai-400001 (BSE Scrip Code: 543389)	The Manager, NSE Limited, Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai- 400051. (NSE Symbol: SIGACHI)
--	--

Dear Sir/Madam,

Sub: Reporting of Monitoring Agency

Unit: Sigachi Industries Limited

Pursuant to Regulation 41(4) of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 read with Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Monitoring Agency Report dated November 12, 2025 issued by **M/s. Kotak Mahindra Bank Limited**, Monitoring Agency in respect of utilization of proceeds of IPO and by **Care Ratings Limited** dated November 13, 2025 in relation to the convertible share warrants issue for the quarter ended September 30, 2025.

This is for your information and records.

Thanking You,

Yours faithfully

For Sigachi Industries Limited

**Vivek Kumar
Company Secretary & Compliance Officer**

Encl: As above.



Registered Office

#229/1 & 90, 2nd Floor, Kalyan's Tulsiram Chambers, Madinaguda, Hyderabad-49, Telangana State, India.
Customer Service +91 40 40114874-76, E-mail: info@sigachi.com, URL: www.sigachi.com

Corporate Office

Plot No. G57/2, Industrial Park, Sultanpur, Hyderabad, Sangareddy (Dist), Telangana - 502319.
Tel No.: +91-8455-242055 / 56 / 57, E-mail: enquiry@sigachi.com, URL: www.sigachi.com



Name of the Issuer: Sigachi Industries Limited

For quarter ended: Sep 30, 2025

Name of the Monitoring Agency: Kotak Mahindra Bank Ltd.

(a) Deviation from the objects: No deviation is observed in the utilisation of issue proceeds

– Utilization different from Objects of the Offer stated in the Prospectus but in line with change of objects approved by shareholders' resolution;

or

– Utilization neither in line with Objects of the Offer stated in the Prospectus nor approved by shareholders' resolution

– In case there is no deviation, the same shall be stated.

(b) Range of Deviation*: NA

Indicate range of percentage deviation from the amount of issue proceeds earmarked for objects. For example, up to 10%, 10 - 25%, 25-50%, 50-75%, 75-100%, not ascertainable etc.

* The range of deviation may be computed by taking weighted average of financial deviation of each object in the ratio of issue proceeds allocated for it. Non-financial deviation may be indicated separately by way of notes.

Declaration:

We declare that this report is based on the format prescribed by the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended. We further declare that this report provides a true and fair view of the utilization of the Offer proceeds.

We declare that we do not have any direct/indirect interest in or relationship with the Company, its promoters, directors, management and also confirm that we do not perceive any conflict of interest in such relationship/interest while monitoring and reporting the utilization of the Offer proceeds by the Company.

Signature:

Name of the Authorized Person/Signing Authority: SUCHITRA NATARAJAN

Designation of Authorized Person/Signing Authority: Suchitra Natarajan – Vice President

Seal of the Monitoring Agency:

Date: 12th Nov, 2025



1) Issuer Details:

Name of the issuer: Sigachi Industries Limited

Names of the promoter: Rabindra Prasad Sinha, Chidambarnathan Shanmuganathan, Amit Raj Sinha and RPS Industries Private Limited

Industry/sector to which it belongs: Pharmaceutical

2) Offer Details:

Offer Period: November 1, 2021 to November 3, 2021

Type of issue (public/rights): Initial Public Offering


Type of specified securities: Equity Shares

Public issue Grading, if any: No credit rating agency registered with SEBI has been appointed for grading the Issue.

Offer size (in Crore): ₹ 125.43 Crore

3) Details of the arrangement made to ensure the monitoring of Offer proceeds:
For expansion of production capacity for microcrystalline cellulose ("MCC") at Dahej, Gujarat;

Particulars	Reply	Comments of the Monitoring Agency	Comments of the Board of Directors
Whether all utilization is as per the disclosures in the Prospectus?	Yes/No	Yes	The Funds have been fully utilized as per offer document, the monitoring agency need not monitor further .
Whether shareholder approval has been obtained in case of material deviations# from expenditures disclosed in the Prospectus?	Yes/No	NA	No Comments
Whether the means of finance for the disclosed Objects of the Offer has changed?	Yes/No	No	No Comments
Is there any major deviation observed over the earlier monitoring agency reports?	Yes/No	No	No Comments
Whether all Government/statutory approvals related to the Object(s) of the Offer have been obtained?	Yes/No	Yes	No Comments
Whether all arrangements pertaining to technical assistance/collaboration are in operation?	Yes/No	No	No Comments
Are there any favorable events improving the viability of these Object(s) of the Offer?	Yes/No	No	No Comments
Are there any unfavorable events affecting the viability of the Object(s) of the Offer?	Yes/No	No	No Comments
Is there any other relevant information that may materially affect the decision making of the investors?	Yes/No	No	No Comments


Kotak Mahindra Bank Ltd.

CIN: L65110MH1985PLC038137

27 BKC, 2nd Floor, C-27, G Block

Bandra Kurla Complex

Bandra (East)

Mumbai - 400 051, Maharashtra

T +91 22 61660000

www.kotak.com

Registered Office:

27 BKC, C 27, G Block,

Bandra Kurla Complex,

Bandra (E), Mumbai 400051,

Maharashtra, India.



Kotak Mahindra Bank

For expansion of production capacity for microcrystalline cellulose ("MCC") at Jhagadia, Gujarat;

Particulars	Reply	Comments of the Monitoring Agency	Comments of the Board of Directors
Whether all utilization is as per the disclosures in the Prospectus?	Yes/No	Yes	The Funds have been fully utilized as per offer document, the monitoring agency need not monitor further
Whether shareholder approval has been obtained in case of material deviations# from expenditures disclosed in the Prospectus?	Yes/No	NA	No Comments
Whether the means of finance for the disclosed Objects of the Offer has changed?	Yes/No	No	No Comments
Is there any major deviation observed over the earlier monitoring agency reports?	Yes/No	No	No Comments
Whether all Government/statutory approvals related to the Object(s) of the Offer have been obtained?	Yes/No	Yes	No Comments
Whether all arrangements pertaining to technical assistance/collaboration are in operation?	Yes/No	No	No Comments
Are there any favorable events improving the viability of these Object(s) of the Offer?	Yes/No	No	No Comments
Are there any unfavorable events affecting the viability of the Object(s) of the Offer?	Yes/No	No	No Comments
Is there any other relevant information that may materially affect the decision making of the investors?	Yes/No	No	No Comments

To manufacture Croscarmellose Sodium ("CCS"), a modified cellulose used as excipient at Dahej, Gujarat (relocated from Kurnool, Andhra Pradesh):

Particulars	Reply	Comments of the Monitoring Agency	Comments of the Board of Directors
Whether all utilization is as per the disclosures in the Prospectus?	Yes/No	No	Utilization is as per the disclosures in the prospectus. The management has decided to shift the project from Kurnool to Dahej SEZ. The same was approved by the shareholders in their AGM held on 07.09.2023. As per offer document the due date for completion of project is Fiscal year 2024, the company seeks extension for completion of project by fiscal year 2026, and the same was approved by shareholders in the EGM held on 05.02.2024.
Whether shareholder approval has been obtained in case of material deviations# from expenditures disclosed in the Prospectus?	Yes/No	Yes	. The Project has shifted from kurnool to Dahej and the same was approved by shareholders in their AGM held on 07.09.2023. As per offer document the due date for completion of project is Fiscal year 2024, the company seeks extension for completion of project by fiscal year 2026, and the same was approved by shareholders in the EGM held on 05.02.2024. The company has commenced the project and 1.18 crore expenditure incurred so far.sss

Kotak Mahindra Bank Ltd.

CIN: L65110MH1985PLC038137

27 BKC, 2nd Floor, C-27, G Block

Bandra Kurla Complex

Bandra (East)

Mumbai - 400 051, Maharashtra

T +91 22 61660000

www.kotak.com

Registered Office:

27 BKC, C 27, G Block,

Bandra Kurla Complex,

Bandra (E), Mumbai 400051,

Maharashtra, India.





Kotak Mahindra Bank

Whether means of finance for the disclosed Objects of the Offer has changed?	Yes/No	No	No change in the means of finance towards objects.
Is there any major deviation observed over the earlier monitoring agency reports?	Yes/No	Yes	No deviation as per earlier Report.
Whether all Government/statutory approvals related to the Object(s) of the Offer have been obtained?	Yes/No	Yes	The company has purchased the plot out of company's internal resources from Dahej SEZ Limited. The said land is already registered in company's favour. The company has got approvals from CTE, GIDC, from Electricity Boards and from environmental clearance from SEIAA on 16.04.2025. The company has received all major approvals from concerned government authorities.
Whether all arrangements pertaining to technical assistance/collaboration are in operation?	Yes/No	No	No Collaborations / technical assistance are in operations.
Are there any favorable events improving the viability of these Object(s) of the Offer?	Yes/No	Yes	The existing Exceipients based manufacturing facilities of the company are located in Gujarat state. So the company is proposed to shift the project location from Kurnool to Dahej SEZ to avail the existing facilities. The same was approved by the shareholders in their AGM held on 07.09.2023.
Are there any unfavorable events affecting the viability of the Object(s) of the Offer?	Yes/No	No	No
Is there any other relevant information that may materially affect the decision making of the investors?	Yes/No	Yes	The company has proposed to shift the CCS Project from Kurnool to Dahej SEZ. The Company has received registered allotment of the plot from Dahej SEZ Limited. The company has got approvals from CTE, GIDC, from Electricity Boards and from environmental clearance from SEIAA on 16.04.2025. Site development and execution commenced. Since the company has received all major approvals from concerned authorities, there were no other factors which materially effect the decision making of the investors.

*Where material deviation may be defined to mean:

a) Deviation in the objects or purposes for which the funds have been raised

b) Deviation in the amount of fund actually utilized by more than 10% of the amount projected in the offer documents.

4) Details of Object(s) of the Offer to be monitored:

(i) Cost of Object(s) of the Offer- INR 110.13 Cr

In ₹ Crore

S l. N o	Item Head	Original Cost (as per Offer Document s)	Revised Cost	Comments of Monitoring Agency	Comments of Board of Directors		
					Reason of cost revision	Proposed financing option	Particular s of firm arrangem ents made
1.	For expansion of production capacity for microcrystalline cellulose ("MCC") at Dahej, Gujarat	28.16	NA	-			

Kotak Mahindra Bank Ltd.

CIN: L65110MH1985PLC038137

27 BKC, 2nd Floor, C-27, G Block

Bandra Kurla Complex

Bandra (East)

Mumbai - 400 051, Maharashtra

T +91 22 61660000

www.kotak.com

Registered Office:

27 BKC, C 27, G Block,

Bandra Kurla Complex,

Bandra (E), Mumbai 400051,

Maharashtra, India.





Kotak Mahindra Bank

2.	For expansion of production capacity for microcrystalline cellulose ("MCC") at Jhagadia, Gujarat	29.24	NA	-	NA
3.	To manufacture Croscarmellose Sodium ("CCS"), a modified cellulose used as excipient at Kurnool, Andhra Pradesh	32.30	NA	Refer *	
4.	General Corporate purposes	20.43	NA	-	
	Total	110.13			

*Object utilisation has changed. The management of the Company has decided to shift the project from Kurnool to Dahej SEZ. The same was approved by the shareholders in their AGM held on 07.09.2023. Further, The company obtained approval from shareholders in the EGM held on 05.02.2024 for completion of the project by fiscal year 2026.

(ii) Progress in the Object(s) of the Offer-

In ₹ Crores

Sr. No	Item Heads	Amount as proposed in Prospectus	Amount utilized			Total unutilized Amount	Comments of Monitoring Agency	Comments of Board of Directors	
			As at Beginning of the quarter	During the quarter	At the end of the quarter			Reason of idle funds	Proposed Course of Action
1.	For expansion of production capacity for microcrystalline cellulose ("MCC") at Dahej, Gujarat	28.16	28.16	0.00	28.16	-	Utilization completed for these objects	NA	NA
2.	For expansion of production capacity for microcrystalline cellulose ("MCC") at Jhagadia, Gujarat	29.24	29.24	0.00	29.24	-			
3.	To manufacture Croscarmellose Sodium ("CCS"), a modified cellulose used as excipient at Kurnool, Andhra Pradesh	32.30	-	0.00	0.00	32.30	Refer (a)		
	Total to be received and monitored in Monitoring Agency Account (A)	89.70	57.40	0.00	57.40	32.30			
4.	General Corporate purposes (B)	20.43	20.43	0.00	20.43	0.00	-		
	Total [(A)+(B)]	110.13	77.83	0.00	77.83	32.30			

a) Object utilization has not yet started. The object remains same however location of the facility is relocated from Kurnool, Andhra Pradesh to Dahej SEZ, Gujarat as per management decision and shareholders special resolution dated 07.09.2023. The company obtained approval from shareholders in the EGM held on 05.02.2024 for completion of the project by fiscal year 2026

(iii) Deployment of unutilized Offer proceeds*-

S. No	Type of instrument where amount invested	Amount invested	Maturity Date	Earnings	Investment (ROI%)	Market Value as at the end of quarter**
1	Fixed Deposit	9,00,00,000	13-May-26	-	8.00%	9,00,00,000
2	Fixed Deposit	5,30,00,000	15-Mar-26	-	8.55%	5,30,00,000
3	Fixed Deposit***	6,00,00,000	10-Mar-26	-	8.25%	6,58,71,388
4	Fixed Deposit	6,00,00,000	15-Mar-26	-	8.55%	6,00,00,000
5	Fixed Deposit	6,00,00,000	15-Mar-26	-	8.55%	6,00,00,000
	Total	32,30,00,000				32,88,71,388


*As on 30 Sep, 2025 the balance in Monitoring Agency Account was Rs. 0.81 Cr.

CIN: L65110MH1985PLC038137

27 BKC, 2nd Floor, C-27, G Block
Bandra Kurla Complex
Bandra (East)
Mumbai - 400 051, Maharashtra

T +91 22 61660000
www.kotak.com

Registered Office:
27 BKC, C 27, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai 400051,
Maharashtra, India.





Kotak Mahindra Bank

**B value is considered

*** Deposit was got matured in Dec 24, the same has been renewed along with interest.

(iv) Delay in implementation of the Object(s) of the Offer-

Object(s) Name	Completion Date		Delay (No. of days/ months)	Comments of Board of Directors		
	As per Prospectus	Actual *		Reason of delay	Proposed Action	Course of Action
For expansion of production capacity for microcrystalline cellulose ("MCC") at Dahej, Gujarat	FY 2023	FY 2024	12 Months	NA		
For expansion of production capacity for microcrystalline cellulose ("MCC") at Jhagadia, Gujarat	FY 2023	FY 2024	12 Months			
To manufacture Croscarmellose Sodium ("CCS"), a modified cellulose used as excipient at Kurnool, Andhra Pradesh	FY 2024	FY 2026	24 Months	No Delay		Present Civil works are under process.

* In case of continuing object(s) please specify latest/revised estimate of completion date.



No. CARE/HRO/GEN/2025-26/1035

The Board of Directors

Sigachi Industries Limited

4th Floor, Kalyan's Tulsiram Chambers,
Madinaguda,
Hyderabad
Telangana - 500049

November 13, 2025

Dear Sir/Ma'am,

Monitoring Agency Report for the quarter ended 30/09/2025 - in relation to the Convertible share warrants issue of Sigachi Industries Limited ("the Company")

We write in our capacity of Monitoring Agency for the Convertible Share Warrants Issue for the amount aggregating to Rs.286.45 crore of the Company and refer to our duties cast under 162A of the Securities & Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations.

In this connection, we are enclosing the Monitoring Agency Report for the quarter ended 30/09/2025 as per aforesaid SEBI Regulations and Monitoring Agency Agreement dated 25/09/2023.

Request you to kindly take the same on records.

Thanking you,

Yours faithfully,



Y Tejeshwar Reddy

Associate Director

tejeshwar.reddy@careedge.in

CARE Ratings Limited

401, Ashoka Scintilla, 3-6-520, Himayat Nagar,
Hyderabad - 500 029
Phone: +91-40-4010 2030

CIN-L67190MH1993PLC071691

4th Floor, Godrej Coliseum, Somaiya Hospital
Road, Off Eastern Express Highway, Sion (East),
Mumbai - 400 022
Phone: +91-22-6754 3456
Email: care@careedge.in • www.careedge.in

Report of the Monitoring Agency

Name of the issuer: Sigachi Industries Limited

For quarter ended: 30/09/2025

Name of the Monitoring Agency: CARE Ratings Limited

(a) Deviation from the objects: Yes

(b) Range of Deviation: The deviation is in terms of timelines and utilization. Funds of Rs.16.75 crore transferred from the MA account to ICDs were not received back within the stipulated period; however, internal accruals of Rs.16.39 crore were utilized in lieu thereof to meet the objects of the issue. While the proceeds were to be fully utilized by September 2025, an amount of Rs.0.43 crore remained unutilized as of September 30, 2025.

Declaration:

We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013.

The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit related analyses. We confirm that there is no conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer, or while undertaking credit rating or other commercial transactions with the entity.

We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title "Comments of the Board of Directors", that shall be captured by the Issuer's Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer's Management/Board.

Signature:



Name and designation of the Authorized Signatory: Y Tejeshwar Reddy

Designation of Authorized person/Signing Authority: Associate Director

CARE Ratings Limited

401, Ashoka Scintilla, 3-6-520, Himayat Nagar,
Hyderabad - 500 029
Phone: +91-40-4010 2030

4th Floor, Godrej Coliseum, Somaiya Hospital
Road, Off Eastern Express Highway, Sion (East),
Mumbai - 400 022
Phone: +91-22-6754 3456
Email: care@careedge.in • www.careedge.in

CIN-L67190MH1993PLC071691

Issuer Details:

Name of the issuer : Sigachi Industries Limited
Name of the promoter : Rabindra Prasad Sinha;
Chidambarnathan Shanmughanathan;
Amit Raj Sinha; and
RPS Industries Private Limited
Industry/sector to which it belongs : Pharmaceuticals & Biotechnology

1) Issue Details

Issue Period : 27/07/2023 to 10/08/2023
Type of issue (public/rights) : Private placement
Type of specified securities : Convertible Share Warrants
IPO Grading, if any : Not applicable
Issue size (in crore) : Rs. 286.45 crore

2) Details of the arrangement made to ensure the monitoring of issue proceeds:

Particulars	Reply	Source of information / certifications considered by Monitoring Agency for preparation of report	Comments of the Monitoring Agency	Comments of the Board of Directors
Whether all utilization is as per the disclosures in the Offer Document?	No	Chartered Accountant certificate*, Bank statements, inter corporate deposit agreement and Offer document (Form PAS-4).	The entire issue proceeds were proposed to be utilized for the objects stated in the offer document by September 2025. However, as of September 30, 2025, an unutilized amount of about Rs. 0.43 crore remains, and the Company has not obtained Board approval for an extension of the utilization timeline. Unutilized funds of Rs. 16.75 crore transferred from the MA account to ICDs were not received back within the stipulated period. However, internal accruals of Rs. 16.39 crore were utilized in lieu thereof to meet the objects of the issue.	The board has considered the note of this.
Whether shareholder approval has been obtained in case of material deviations# from expenditures disclosed in the Offer Document?	Not Applicable		No material deviations	Not applicable
Whether the means of finance for the disclosed objects of the issue have changed?	Yes		The company has not received Rs 68.63 crore which will result in change in means of finance to that stipulated in the objects. Further, there could be a delay in implementation	The board has considered the note of this.

CARE Ratings Limited

401, Ashoka Scintilla, 3-6-520, Himayat Nagar,
Hyderabad - 500 029
Phone: +91-40-4010 2030



Corporate Office :4th Floor, Godrej Coliseum,
Somaiya Hospital Road, Off Eastern Express
Highway, Sion (E), Mumbai - 400 022
Phone: +91-22-6754 3456 • www.careedge.in

CIN-L67190MH1993PLC071691

Particulars	Reply	Source of information / certifications considered by Monitoring Agency for preparation of report	Comments of the Monitoring Agency	Comments of the Board of Directors
			of the capex.	
Is there any major deviation observed over the earlier monitoring agency reports?	No		As per previous MA report.	Not applicable
Whether all Government/statutory approvals related to the object(s) have been obtained?	Yes		As per the CA certificate and management certificate, the company has requisite approvals in place for the existing plants in Gujarat. SIL may require fresh approvals for the manufacturing plant to be reconstructed in Hyderabad.	The board has considered the note of this.
Whether all arrangements pertaining to technical assistance/collaboration are in operation?	Not applicable		No collaborations/technical assistance in operations.as mentioned by the CA certificate and management confirmation.	Not applicable
Are there any favorable/unfavorable events affecting the viability of these object(s)?	Yes		Out of the total issue, Rs 68.63 crore has not been received from the warrant holders within the stipulated timeline. Additionally, the unfavorable fire incident at the Hyderabad facility is expected to have adverse impact on the planned capex and expansion initiatives, which are now unlikely to progress as originally envisaged.	The board has considered the note of this.
Is there any other relevant information that may materially affect the decision making of the investors?	Yes	Chartered Accountant certificate*, Bank statements, inter corporate deposit agreement and Offer document (Form PAS-4).	Of the envisaged promoter investment of Rs 135.72 crore, 41% of the funds (i.e. Rs 56.77 crore) have not been infused by the promoters. The major fire incident that happened at Hyderabad facility in Q1FY26 may materially affect the decision making of investors. Till end of Q1FY26, unutilized funds were parked in ICDs amounting to Rs. 16.75 crores and FDs amounting to Rs. 3.16 crores. During Q2FY26, company had claimed utilization as reimbursement towards the capex incurred during April 2023 to March 2025, which was met through internal accruals. The company provided invoices and bank statements.	The board has considered the note of this.

*Chartered Accountant certificate from Yelamanchi & Associates (Statutory auditor) dated October 21, 2025

#Where material deviation may be defined to mean:

- Deviation in the objects or purposes for which the funds have been raised
- Deviation in the amount of funds actually utilized by more than 10% of the amount projected in the offer documents

CARE Ratings Limited

TR

401, Ashoka Scintilla, 3-6-520, Himayat Nagar,
Hyderabad - 500 029
Phone: +91-40-4010 2030

Corporate Office :4th Floor, Godrej Coliseum,
Somaiya Hospital Road, Off Eastern Express
Highway, Sion (E), Mumbai - 400 022
Phone: +91-22-6754 3456 • www.careedge.in

CIN-L67190MH1993PLC071691

3) Details of objects to be monitored:

(i) Cost of objects –

Sr. No	Item Head	Source of information / certifications considered by Monitoring Agency for preparation of report	Original cost (as per the Offer Document) in Rs. Crore	Revised Cost in Rs. Crore	Comments of the Monitoring Agency	Comments of the Board of Directors		
						Reason for cost revision	Proposed financing option	Particulars of - firm arrangements made
1	Acquisition / Expansion of Active Pharmaceutical Ingredients (API) manufacturing facility	Chartered Accountant certificate*, Bank statements, offer document and Inter-corporate deposit agreement and receipt.	160.00	NA	NA	Not applicable		
2	Upgradation/Expansion of existing Manufacturing facilities at Dahej and Jhagadia		50.00	NA	NA	Not applicable		
3	Upgradation/Expansion of existing Manufacturing facility at Hyderabad		22.10	21.45	The difference of Rs 0.65 crore is on account of under-subscription of 25,000 share warrants.	The board has considered the note of this.		
4	Working Capital		30.00	NA	NA	Not applicable		
5	General Corporate Purposes		25.00	NA	NA	Not applicable		
Total			286.45					

* Chartered Accountant certificate from Yelamanchi & Associates (Statutory auditor) dated October 21, 2025

(ii) Progress in the objects –

Sr. No	Item Head	Source of information / certifications considered by Monitoring Agency for preparation of report	Amount as proposed in the Offer Document in Rs. Crore	Amount raised till September 30, 2025 (Rs. crore)	Amount utilised in Rs. Crore			Total unutilised amount in Rs. crore	Comments of the Monitoring Agency	Comments of the Board of Directors	
					As at beginning of the quarter in Rs. Crore	During the quarter in Rs. Crore	At the end of the quarter in Rs. Crore			Reasons for idle funds	Proposed course of action
1	Acquisition / Expansion of Active Pharmaceutical Ingredients (API) manufacturing facility	Chartered Accountant certificate*, Bank statements, offer document and	160.00	217.82	86.51	-	86.51	0.00	The company spent Rs 92.91 crore, of which Rs 86.51 crore was funded through preferential issue proceeds and balance of Rs 6.40 crore was funded through internal accruals. The company	Not applicable	

CARE Ratings Limited

TR

401, Ashoka Scintilla, 3-6-520, Himayat Nagar,
Hyderabad - 500 029
Phone: +91-40-4010 2030

Corporate Office :4th Floor, Godrej Coliseum,
Somaia Hospital Road, Off Eastern Express
Highway, Sion (E), Mumbai - 400 022
Phone: +91-22-6754 3456 • www.careedge.in

CIN-L67190MH1993PLC071691

Sr. No	Item Head	Source of information / certifications considered by Monitoring Agency for preparation of report	Amount as proposed in the Offer Document in Rs. Crore	Amount raised till September 30, 2025 (Rs. crore)	Amount utilised in Rs. Crore			Total unutilised amount in Rs. crore	Comments of the Monitoring Agency	Comments of the Board of Directors	
					As at beginning of the quarter in Rs. Crore	During the quarter in Rs. Crore	At the end of the quarter in Rs. Crore			Reasons for idle funds	Proposed course of action
		Fixed deposit receipt.							transferred Rs 6.40 crore in Q1FY25 to the Preferential issue account from CC account.		
2	Upgradation/Expansion of existing Manufacturing facilities at Dahej and Jhagadia		50.00		50.00	-	50.00	0.00	Fully utilized.		Not applicable
3	Upgradation/Expansion of existing Manufacturing facility at Hyderabad		21.45		-	19.48	19.48	0.43	At the end of Q1FY26, SIL had unutilized funds of Rs. 16.75 crore parked in intercorporate deposits (ICDs) and Rs.3.16 crore in fixed deposits (FDs). During Q2FY26, the company had claimed utilization as reimbursement towards capex at the Hyderabad facility for the period April 2023 to March 2025, using Rs. 16.39 crore from internal accruals and the balance Rs.3.09 crore through redemption of FD. The cash flow transaction involved transfer of internal accruals from the current account of Sigachi to the monitoring account, followed by a reimbursement transfer from the monitoring account to the cash credit (CC) account. The company has provided the relevant bank statements and supporting invoices in this regard.		Not applicable
4	Working Capital		30.00		36.40	-	36.40	0.00	Out of Rs 36.40 crore, Rs 30 crore was utilized towards working capital requirements as per the specified object. Rs 6.40 crore was transferred		Not applicable

CARE Ratings Limited

401, Ashoka Scintilla, 3-6-520, Himayat Nagar,
Hyderabad - 500 029
Phone: +91-40-4010 2030

TR

Corporate Office :4th Floor, Godrej Coliseum,
Somaiya Hospital Road, Off Eastern Express
Highway, Sion (E), Mumbai - 400 022
Phone: +91-22-6754 3456 • www.careedge.in

CIN-L67190MH1993PLC071691

Sr. No	Item Head	Source of information / certifications considered by Monitoring Agency for preparation of report	Amount as proposed in the Offer Document in Rs. Crore	Amount raised till September 30, 2025 (Rs. crore)	Amount utilised in Rs. Crore			Total unutilised amount in Rs. crore	Comments of the Monitoring Agency	Comments of the Board of Directors	
					As at beginning of the quarter in Rs. Crore	During the quarter in Rs. Crore	At the end of the quarter in Rs. Crore			Reasons for idle funds	Proposed course of action
									from the CC account to the preferential issue account in Q1-FY25, which was utilized towards Object 1.		
5	General Corporate Purposes		25.00		25.00	-	25.00	-	Fully utilized.		Not applicable
Total			286.45	217.82	197.91	19.48	217.39	0.43			

*Chartered Accountant certificate from Yelamanchi & Associates (Statutory auditor) dated October 21, 2025.

(iii) Deployment of unutilized proceeds:

Sr. No.	Type of instrument and name of the entity invested in	Amount invested	Maturity date	Earning	Return on Investment (%)	Market Value as at the end of quarter
1	Fixed Deposit, SBM Bank	0.36*	15-03-2026	-	8.55%	0.36
2	Preferential issue account, Kotak Mahindra Bank	0.07	NA	NA	NA	NA
	Total	0.43				

*The offer does not specify a mode in which unutilized funds can be parked. The Board may take note of this.

#Company had made a fixed deposit of Rs 5.30 crore with SBM Bank of which Rs 0.36 crore is from preferential issue proceeds and balance from internal cash flows.

Note: Inlieu of unutilized funds parked in Intercompany deposits with Kaycee Finstock Private Limited for about Rs. 16.75 crores, Sigachi has transferred its own funds about Rs. 16.39 crores to utilize the funds towards objects of the issue and availed extension for ICDs for about one year in the month of August 2025. Remaining unutilized proceeds of Rs. 0.43 crores, of which Rs. 0.36 crores shown in FDs created from internal accruals and Rs. 0.07 crores continue to be in MA account.

(iv) Delay in implementation of the object(s) –

Objects	Completion Date		Delay (no. of days/ months)	Comments of the Board of Directors	
	As per the offer document	Actual		Reason of delay	Proposed course of action
Acquisition / Expansion of Active Pharmaceutical Ingredients (API) manufacturing facility	2 Years from the date of receipt of proceeds (i.e., Q2 - FY26)	Ongoing*	NA		Not applicable
Upgradation/Expansion of existing Manufacturing facilities at Dahej and Jhagadia		Completed	NA		Not applicable
Upgradation/Expansion of existing Manufacturing facility at Hyderabad		Ongoing*	NA		Not applicable
Working Capital		Completed	NA		Not applicable
General Corporate Purposes		Completed	NA		Not applicable

CARE Ratings Limited

401, Ashoka Scintilla, 3-6-520, Himayat Nagar,
Hyderabad - 500 029
Phone: +91-40-4010 2030

TR

Corporate Office :4th Floor, Godrej Coliseum,
Somaiya Hospital Road, Off Eastern Express
Highway, Sion (E), Mumbai - 400 022
Phone: +91-22-6754 3456 • www.careedge.in

CIN-L67190MH1993PLC071691

**While the outer timeline is 2 years from the date of receipt of proceeds i.e September 2025, for implementation of the above objects, actual progress towards the same is unascertainable. Detailed schedule for the project implemetation is not available. Company has not taken any board approval for deviation in timelines for non utilisation of Rs. 0.43 crores within the specified timelines.*

4) Details of utilization of proceeds stated as General Corporate Purpose (GCP) amount in the offer document:

Sr. No	Item Head^	Amount in Rs. Crore	Source of information / certifications considered by Monitoring Agency for preparation of report	Comments of Monitoring Agency	Comments of the Board of Directors
1	Working Capital	25.00	Chartered Accountant certificate*, Bank statements and offer document	Form PAS-4 does not explicitly define the scope of General Corporate Purpose. Company has transferred Rs 25 crore to CC account from preferential issue account towards working capital purpose.	The board has considered the note of this
	Total	25.00			

** Chartered Accountant certificate from Yelamanchi & Associates (Statutory auditor) dated October 21, 2025*

TR

CARE Ratings Limited

401, Ashoka Scintilla, 3-6-520, Himayat Nagar,
Hyderabad - 500 029
Phone: +91-40-4010 2030

CIN-L67190MH1993PLC071691

Corporate Office :4th Floor, Godrej Coliseum,
Somaia Hospital Road, Off Eastern Express
Highway, Sion (E), Mumbai - 400 022
Phone: +91-22-6754 3456 • www.careedge.in

Disclaimers to MA report:

- a) This Report is prepared by CARE Ratings Ltd (hereinafter referred to as “**Monitoring Agency/MA**”). The MA has taken utmost care to ensure accuracy and objectivity while developing this Report based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever.
- b) This Report has to be seen in its entirety; the selective review of portions of the Report may lead to inaccurate assessments. For the purpose of this Report, MA has relied upon the information provided by the management /officials/ consultants of the Issuer and third-party sources like statutory auditor which is peer reviewed audit firm appointed by the Issuer believed by it to be accurate and reliable.
- c) Nothing contained in this Report is capable or intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The MA is also not responsible for any errors in transmission and specifically states that it, or its directors, employees do not have any financial liabilities whatsoever to the users of this Report.
- d) The MA and its affiliates do not act as a fiduciary. The MA and its affiliates also do not act as an expert to the extent defined under Section 2(38) of the Companies Act, 2013. While the MA has obtained information from sources it believes to be reliable, it does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives from statutory auditors which is peer reviewed audit firm, lawyers, chartered engineers or other experts, and relies on in its reports.
- e) The MA or its affiliates may have other commercial transactions with the entity to which the report pertains. As an example, the MA may rate the issuer or any debt instruments / facilities issued or proposed to be issued by the issuer that is subject matter of this report. The MA may receive separate compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors.

**CARE Ratings Limited**

401, Ashoka Scintilla, 3-6-520, Himayat Nagar,
Hyderabad - 500 029
Phone: +91-40-4010 2030

CIN-L67190MH1993PLC071691

4th Floor, Godrej Coliseum, Somaiya Hospital
Road, Off Eastern Express Highway, Sion (East),
Mumbai - 400 022
Phone: +91-22-6754 3456
Email: care@careedge.in • www.careedge.in